Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for BEAM-302 in Alpha-1 Antitrypsin Deficiency. The expected timing is based on the latest available company guidance and may change.
03/25/26:- Updated Ph1/2 data; 60 mg selected. Global pivotal cohort expected to initiate in H2 2026. 05/07/26:- FDA feedback supports accelerated approval; pivotal ~50-patient AATD cohort to start H2 2026; 2026 congress data. 05/18/26:- ATS detailed Ph1/2 durability and safety shown. Pivotal cohort initiation reiterated for H2 2026; more 2026 congress data. 07/23/26:- Updated Ph1/2 data to be presented at ERS 2026 on Sep 8, 2026. Pivotal cohort still expected H2 2026. 08/04/26:- First pivotal cohort patient dosed. Updated Ph1/2 data selected for ERS 2026, Sep 5-9.
Verification
Confirm timing and program details against the company announcement or filing.